Voclosporin · Lupkynis
Small molecule
Evidence outlook
Approved: Lupus Nephritis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also in development:Systemic Lupus Erythematosus · Phase 3 · investigational in the US
Also approved (2)
- Lupus nephritis, in combination with mycophenolate mofetil
- Active lupus nephritis in adults (with mycophenolate mofetil)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
AURORA NCT03021499 · Lupus Nephritis This was a randomized, quadruple-blind, placebo-controlled trial with 357 participants, and its hard clinical renal-response endpoint at Week 52 was met: 73 of 179 participants responded with voclosporin versus 40 of 178 with placebo (p<0.001). Voclosporin was tested as an add-on to mycophenolate mofetil and corticosteroids. Registry: NCT03021499 | 3 | Number of Participants With Adjudicated Renal Response at Week 52 (52 Weeks) 2019-09-24 | Number of Participants With Adjudicated Renal Response at Week 52 (52 Weeks): Voclosporin — Number of renal responders: 73/179 (40.8%); Number of renal non-responders: 106/179 (59.2%) vs Placebo Oral Capsule — Number of renal responders: 40/178 (22.5%); Number of renal non-responders: 138/178 (77.5%) | Reliable signal | link ↗ |
View 1 more trial
AURORA 2 NCT03597464 · Lupus Nephritis This trial explicitly enrolled only patients who completed 52 weeks of treatment in the prior AURORA 1 study, making it a blinded, randomized, placebo-controlled continuation (extension) of that earlier trial rather than a fresh confirmatory study. Its primary endpoint was a descriptive safety/adverse-event comparison (no formal statistical test), so while the design retained randomization and blinding, it does not represent a newly met hard efficacy endpoint on its own. Its registered primary outcome on ClinicalTrials.gov is "Adverse Events (AE) Profile and Routine Biochemical and Hematological Assessments.". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak. Registry: NCT03597464 | 3 | Adverse Events (AE) Profile and Routine Biochemical and Hematological Assessments. (Month 12 (AURORA 2 baseline) to Month 36) 2021-10-07 | Adverse Events (AE) Profile and Routine Biochemical and Hematological Assessments. (Month 12 (AURORA 2 baseline) to Month 36): Voclosporin — Any treatment-emergent adverse event (TEAE): 100 Participants; Treatment-related TEAE: 28 Participants; Serious TEAE: 21 Participants; TEAE leading to study drug discontinuation: 11 Participants; TEAE leading to death: 0 Participants; Treatment-related TEAE leading to death: 0 Participants; Disease-related TEAE: 50 Participants; Disease-related serious TEAE: 7 Participants | Placebo Oral Capsule — Any treatment-emergent adverse event (TEAE): 80 Participants; Treatment-related TEAE: 21 Participants; Serious TEAE: 23 Participants; TEAE leading to study drug discontinuation: 17 Participants; TEAE leading to death: 3 Participants; Treatment-related TEAE leading to death: 0 Participants; Disease-related TEAE: 34 Participants; Disease-related serious TEAE: 11 Participants | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (10)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (3)
What this study did
What this study did
What this study did
Phase 4 (3)
What this study did
What this study did
What this study did
Competitive landscape
Other Calcineurin drugs
Cyclosporine (Vevye), Extended-release tacrolimus (VI-0106), nanosomal tacrolimus. Compare all 4 Calcineurin drugs
3 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Lupus Nephritis: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Voclosporin (Lupkynis): this drug | Approved | Small molecule | Calcineurin, Cyclophilin A (leading to calcineurin inhibition) | Reliable signal | NCT03021499: Number of Participants With Adjudicated Renal Response at Week 52 (52 Weeks): Voclosporin — Number of renal responders: 73/179 (40.8%); Number of renal non-responders: 106/179 (59.2%) vs Placebo Oral Capsule — Number of renal responders: 40/178 (22.5%); Number of renal non-responders: 138/178 (77.5%) | |
| Belimumab (GSK1550188) (Benlysta) | Approved | Monoclonal antibody | BAFF / BLyS (B-lymphocyte stimulator), BAFF (BLyS) | Reliable signal | No reviewed efficacy summary in this indication | |
| Cyclosporine (Vevye) | Approved(overall) | Small molecule | Calcineurin | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Obinutuzumab | Approved | Monoclonal antibody | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| Repository Corticotropin (Acthar Gel) | Approved | Peptide | Melanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Extended-Release Tacrolimus (VI-0106) | Phase 3(overall) | Small molecule | Calcineurin | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Ebribafusp Alfa | Phase 2 | Protein / enzyme therapeutic | C3d / Factor H | not yet graded | No reviewed efficacy summary in this indication | |
| Nanosomal Tacrolimus | Phase 2(overall) | Small molecule | Calcineurin | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Rapcabtagene Autoleucel | Phase 2 | Undisclosed | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-2173 | Phase 2 | Undisclosed | IFNAR1 / TACI | not yet graded | No reviewed efficacy summary in this indication | |
| Vonsetamig | Phase 1 | — | BCMA x CD3 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Lupkynis (Voclosporin) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.